Loading…
H.R. 5160119th CongressPassed one chamberLatest action Jul 21, 2026Decoded by AI · checked against the record
Official title: Stem Cell Therapeutic and Research Reauthorization Act of 2025
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
HR 5160 renews two federal transplant-match programs through 2031 and raises yearly funding to roughly $33M starting in 2027.
50-second read · 5 questions answered below
HR 5160 renews the C.W. Bill Young Cell Transplantation Program and the federal cord blood inventory program through 2031. Both programs have been in place since 2005 and are unchanged in structure. The bill does not create any new programs.
Patients with blood diseases such as leukemia or sickle cell disease who need stem cell or bone marrow transplants and lack a family donor are the primary population served. Hospitals, transplant centers, and cord blood banks that rely on these national registries are also affected.
Without continued federal authorization, the national registries and cord blood banks that support donor matching would lose their funding base. Patients who depend on those registries to find unrelated donors would face gaps in the availability of matching and stored cord blood supplies.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it passed the House, and the official record shows nothing new since. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.